BioPharma Updates 21st July, 2025

BioPharma Updates, July 21st, 2025.

SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations, including Funding, Initial Public Offerings, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below, with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.

Download this update:

View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.

Funding

• Illimis Therapeutics (Seoul, South Korea) raised $28M in Series B funding to accelerate development of GAIA-based Alzheimer’s therapeutics, expand to immune disorders, and advance global R&D collaborations.
• Prime Medicine, Inc. (MA, USA) received an additional $24M from the Cystic Fibrosis Foundation to advance development of its prime editing gene therapy targeting the G542X mutation in cystic fibrosis.
• One Biosciences (Paris, France) raised $16.3M in Series A funding to advance its AI-driven single-cell transcriptomic platform OneMap™ and expand partnerships with pharma and biotech companies.
• Oncomatryx Biopharma (Derio, Spain) received ~$13.6M from the EIC Accelerator to advance clinical trials for its lead ADC candidate and expand operations targeting immune-cold solid tumors.
• Ciloa SAS (Montpellier, France) raised $7.6 million in government-backed funding under the France 2030 initiative. The funds will advance its exosome-based therapy, APN-sEV, targeting metabolic diseases like type 2 diabetes and obesity.
• Daré Bioscience, Inc. (CA, USA) received $6M in non-dilutive funding from a multi-year grant provided by the Bill & Melinda Gates Foundation to support development of DARE-LARC1, a programmable long-acting contraceptive implant.
• Tomoverse Imaging (Montreal, Canada) raised $5M in a Seed funding to complete development of its AI-powered cardiac CT imaging platform, advance clinical studies, and support regulatory and commercialization efforts across global markets.
• CDX Medical Technologies (MA, USA) raised $2.5M in a Series A to complete regulatory testing, pursue market approval, and initiate commercialization of its next-generation ECMO pump platform.

Emerging

• Renasant Bio (CA, USA) launched with $54.5M in seed funding to develop oral small molecule corrector and potentiator therapies targeting the underlying biology of autosomal dominant polycystic kidney disease (ADPKD).

Post IPO Equity

• Ascentage Pharma (Suzhou, China) raised $192.3M to support commercialization, clinical development of core candidates, infrastructure, and global operations.
• GT Medical Technologies, Inc. (AZ, USA) raised $53M in an oversubscribed Series D equity financing to expand U.S. commercialization of GammaTile® Therapy and complete clinical trials for brain metastases and glioblastoma.
• Milestone Pharmaceuticals (Montreal, Canada) raised $52.5M through an underwritten public offering of common shares to fund the clinical development and planned launch of etripamil for PSVT, as well as for working capital and general corporate purposes.
• BriaCell Therapeutics Corp. (PA, USA) raised $15M to support working capital, corporate operations, and business advancement.
• Citius Oncology, Inc. (NJ, USA) raised $9M through a public offering of common stock and warrants to support the commercialization of LYMPHIR, fund licensing milestone payments, and cover general corporate expenses.
• CEL-SCI (VA, USA) raised $5.7M through a best-efforts public offering of common stock to fund continued development of its cancer immunotherapy candidate Multikine, as well as for general corporate purposes and working capital.
• 60 Degrees Pharmaceuticals (DC, USA) raised $5M through a public offering of common stock and warrants to fund working capital and general corporate purposes.
• OS Therapies (NY, USA) raised $4.2M through a warrant exercise inducement and exchange offer to fund regulatory efforts for OST-HER2 in osteosarcoma, close its prostate cancer study, advance AI-driven tADC development, and support strategic alternatives for its OS Animal Health unit.
• NKGen Biotech (CA, USA) raised $2M through a common equity PIPE to support development of its NK cell therapy troculeucel and regain compliance with listing and reporting obligations.
• Avicanna Inc. (Toronto, Canada) raised $1M through a non-brokered private placement to support working capital, manufacturing, and research and clinical development activities.
• Gain Therapeutics (MD, USA) announced a proposed underwritten public offering of common stock and warrants to fund the continued development of its lead candidate GT-02287 for neurodegenerative diseases and support general corporate purposes.

Post IPO debt

• Median Technologies (Valbonne, France) raised ~$40.8M in debt financing agreement with the European Investment Bank to support the commercial launch of its AI-powered lung cancer screening software eyonis® LCS in the U.S. and Europe, and to advance its broader oncology imaging suite.
• Aptose Biosciences (CA, USA) received a $2M loan advance from Hanmi Pharmaceutical as part of an $8.5M loan facility to support the clinical development of its lead AML candidate, tuspetinib, in combination frontline therapy.
• BioNxt Solutions (Vancouver, Canada) raised $1.2M through a convertible debt offering to fund product development, commercialization, intellectual property filings, and general working capital.

Mergers and Acquisitions

• Sino Biopharmaceutical (Hong Kong) to acquire Lanova Medicines (Shanghai, China) for up to $951M for pipeline expansion in oncology and immunology.
• Laboratoires Dermatologiques d’Uriage SAS (France) to acquire HRA Pharma (Paris, France) ’s dermacosmetics business for up to $327M for strategic portfolio optimization.
• LEO Pharma (Neu Isenburg, Germany) to acquire rights from Boehringer Ingelheim (Ingelheim Am Rhein, Germany) to develop and commercialize top-line atopic dermatitis drug for $98M to strengthen dermatology pipeline.
• Zimmer Biomet (IN, USA) to acquire Monogram Orthopaedics Inc. (TX, USA) for $75M to expand its robotics suite with autonomous solutions.
• Xenotherapeutics Inc. (MA, USA) to acquire ESSA Pharma Inc. (TX, USA) for $40M for pipeline expansion in prostate cancer therapeutics.
• Waters Corporation (MA, USA) to acquire Danaher Corporation’s Biosciences and Diagnostic Solutions business (DC, USA) for strategic expansion into regulated high-volume life science and diagnostics testing. 
• TandemAI (NY, USA) to acquire Perpetual Medicines (MA, USA) to expand physics and AI-based drug discovery capabilities.
• Longevity Health Holdings (PA, USA) to acquire THPlasma (NJ, USA) to strengthen its position in the plasma collection and healthcare services sector.
• Evestia Clinical (Letchworth Garden City, United Kingdom) to acquire Atlantic Research Group (VA, USA) to expand global clinical trial capabilities and therapeutic expertise. 
• Inmagene Biopharmaceuticals (CA, USA) to acquire Ikena Oncology (MA, USA) to combine immunology and oncology pipelines and expand global development capabilities.
• Sorcero (DC, USA) to acquire Axiom Health (CA, USA) to integrate AI-driven insights across life sciences and medical device markets.
• Safe Life AB (Solna, Sweden) to acquire HTM Medico (Singapore) to expand presence in Asia and strengthen medical technology offerings.
• Onconetix (OH, USA) to acquire Ocuvex Therapeutics (NJ, USA) to advance clinical-stage ocular disease programs and expand ophthalmic pipeline.
• I-Mab BioPharma (MD, USA) to acquire Bridge Health (Bengaluru, India) for strategic expansion of Givastomig intellectual property portfolio.

Partnerships

• JCR Pharmaceuticals (Ashiya, Japan) and Acumen Pharmaceuticals (VA, USA) announced a ~$555M global option and license agreement to develop Alzheimer’s therapies combining JCR’s J-Brain Cargo® BBB-penetrating platform with Acumen’s AβO-selective antibodies.
• Repare Therapeutics (Montreal, Canada) and Debiopharm (Lausanne, Switzerland) announced a ~$267M exclusive worldwide licensing agreement for lunresertib, a first-in-class PKMYT1 inhibitor.
• Nicox (Valbonne, France) and Kowa (Japan) announced a ~$208M exclusive global licensing agreement for NCX 470 to support development and commercialization of the glaucoma therapy outside Asia.
• ViiV Healthcare (United Kingdom) and the Medicines Patent Pool (Geneva, Switzerland) announced an expanded licensing partnership to include long-acting cabotegravir for HIV treatment, enabling generic manufacturers to develop and supply affordable versions across 133 countries in line with new WHO guidelines.
• Boehringer Ingelheim (Germany) and LEO Pharma (Denmark) announced an exclusive global license and transfer agreement for SPEVIGO® to accelerate access and development of the IL-36-targeting therapy for generalized pustular psoriasis and other potential dermatologic indications.
• Golden Age Health (Singapore) and Innostellar Biotherapeutics (China) announced a ten-year exclusive promotional partnership to commercialize LX-101, a gene therapy for RPE65-related inherited retinal dystrophies, in mainland China.
• CEL-SCI (VA, USA) and a leading Saudi pharmaceutical company announced a partnership to file for Breakthrough Medicine Designation and commercialize Multikine in Saudi Arabia, with plans to expand access across the MENA region.
• Made Scientific (NJ, USA) and Sentinel BioTherapeutics (TX, USA) announced a strategic manufacturing partnership to support Phase I/II clinical development of SENT-001, an allogeneic encapsulated IL-2 cell therapy for solid tumors.
• 365mc (Seoul, South Korea) and Raziel Therapeutics (Rehovot, Israel) announced a strategic partnership to jointly advance Phase 3 clinical development and commercialization of RZL-012, an injectable treatment for focal fat reduction, in South Korea.
• Bio-Techne (MN, USA) and Spear Bio (MA, USA) announced a strategic partnership to distribute next-generation ultrasensitive immunoassays for detecting low-abundance neurological biomarkers, initially focusing on Alzheimer’s disease research.
• AATec Medical (Germany) and Northway Biotech (Lithuania) announced a partnership to develop and scale manufacturing of ATL-105, a recombinant inhaled alpha-1 antitrypsin therapy targeting non-CF bronchiectasis and other respiratory diseases.
• Bioz (CA, USA) and SOPHiA GENETICS (Rolle, Switzerland) announced a strategic partnership to integrate Bioz Badges and a custom Content Hub into SOPHiA’s platform, enhancing transparency and scientific validation for users of the SOPHiA DDM™ Platform.
• Thermo Fisher Scientific (MA, USA) and Sanofi (France) announced an expanded strategic partnership under which Thermo Fisher will acquire Sanofi’s sterile manufacturing site in New Jersey to boost U.S. drug product capacity and continue producing therapies for Sanofi.
• Allarity Therapeutics (MA, USA) and an undisclosed EU-based biotech company announced a commercial agreement granting non-exclusive global rights to Allarity’s DRP® algorithms for breast cancer, along with transcriptome analysis services to support precision oncology development.

Initial Public Offering (IPO)

• Carlsmed (CA, USA) announced a proposed $100.5M public offering to support its AI-enabled personalized spine surgery platform and fund future growth initiatives.

Registered Direct Offering (RDO)

• Rani Therapeutics (CA, USA) raised $3M through a registered direct offering of common stock and pre-funded warrants to support general corporate purposes and ongoing operations.

Closures and Layoffs

• Karyopharm Therapeutics (MA, USA) to lay off 20% of employees for ongoing management of operating expenses as it explores a sale or merger.
• Azurity Pharmaceuticals (MA, USA) to lay off 75 employees for operational reasons.
• Pacira BioSciences (FL, USA) to lay off 71 employees for manufacturing efficiency improvements.
• Ventus Therapeutics (MA, USA) to lay off employees for pipeline prioritization and investment in machine learning and phase 2 trial readiness. 
• GSK (GlaxoSmithKline) (Brentford, United Kingdom) to lay off a very limited number of employees for continued R&D investment prioritization. 
• Sarepta Therapeutics (MA, USA) to lay off 500 employees for strategic pivot to siRNA and label warning on Elevidys.
• Sail Biomedicines (MA, USA) to lay off 36 employees for strategic pipeline prioritization.

Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.